Viatris Inc. Common Stock
$16.95
-$0.18 (-1.05%)
$16.91Day Range$17.20
Key Statistics
Market Cap
$19.47B
Shares Outstanding
1,148.6M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 23, 1973
Round Lot
100
Locale
US
Trading Data
Day Open
$17.19
Day High
$17.20
Day Low
$16.91
Volume
15.65M
VWAP
$16.97
Prev Close
$17.13
Transactions
--
Acc. Volume
--
About Viatris Inc. Common Stock
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
PHARMACEUTICAL PREPARATIONSSIC 283430,000 employees1000 MYLAN BOULEVARD, CANONSBURG, PA, 15317(724) 514-1465IPO Feb 23, 1973US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001792044
- Composite FIGI
- BBG00Y4RQNH4
- Share Class FIGI
- BBG00Y52JV51
- Ticker Root
- VTRS
- SIC Code
- 2834
About Viatris Inc. Common Stock (VTRS) Stock
Viatris Inc. Common Stock (VTRS) closed the 2026-09-18 session at $16.95, down 1.05% versus the previous close (-0.18). The stock opened at $17.19 and traded between $16.91 and $17.20 during that session. Session trading volume was 15.6M shares. The volume-weighted average price (VWAP) is $16.97.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Viatris Inc. Common Stock has a market capitalization of $19.47 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. VTRS is listed on the XNAS exchange. The company employs approximately 30,000 people. Viatris Inc. Common Stock is headquartered in CANONSBURG, PA. The recorded listing date is 1973-02-23.
On this page you can find market VTRS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.